ProShare Advisors
EWTX icon

ProShare Advisors’s Edgewise Therapeutics EWTX Stock Holding History

ProShare Advisors’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$459K Sell
14,578
-2,398
-14% -$69.2K ﹤0.01% 1112
2025
Q4 		$421K Buy
16,976
+1,685
+11% +$33.8K ﹤0.01% 1231
2025
Q3 		$248K Sell
15,291
-3,597
-19% -$51K ﹤0.01% 1564
2025
Q2 		$248K Sell
18,888
-1,315
-7% -$19K ﹤0.01% 1577
2025
Q1 		$444K Sell
20,203
-4,725
-19% -$124K ﹤0.01% 1162
2024
Q4 		$666K Buy
24,928
+5,669
+29% +$181K ﹤0.01% 1108
2024
Q3 		$514K Buy
19,259
+5,769
+43% +$115K ﹤0.01% 1114
2024
Q2 		$243K Sell
13,490
-3,395
-20% -$59.2K ﹤0.01% 1425
2024
Q1 		$308K Buy
16,885
+5,748
+52% +$91.4K ﹤0.01% 1414
2023
Q4 		$122K Buy
+11,137
New +$78.2K ﹤0.01% 1753
2023
Q1 		– Sell
-10,105
Closed -$90.3K – 1832
2022
Q4 		$90.3K Buy
+10,105
New +$94.7K ﹤0.01% 1669
2022
Q2 		– Sell
-12,378
Closed -$120K – 1904
2022
Q1 		$120K Sell
12,378
-3,015
-20% -$38.8K ﹤0.01% 1997
2021
Q4 		$235K Buy
+15,393
New +$277K ﹤0.01% 1929

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ProShare Advisors's EWTX Position: Q1 2026 in Review

ProShare Advisors reduced its Edgewise Therapeutics (EWTX) stake by 14% in Q1 2026, selling an estimated $69.2K and leaving 14,578 shares worth $459K. The position accounts for ﹤0.01% of the portfolio, ranked #1112.

ProShare Advisors first reported a position in EWTX in Q4 2021 and has held it in 13 quarters since. The position peaked at $666K in Q4 2024. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • ProShare Advisors held 14,578 shares of Edgewise Therapeutics worth $459K as of Q1 2026.
  • ProShare Advisors sold 2,398 Edgewise Therapeutics shares in Q1 2026, an estimated $69.2K.
  • Edgewise Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #1112 holding.
  • ProShare Advisors first reported a position in Edgewise Therapeutics in Q4 2021 and has held it in 13 quarters since.
  • ProShare Advisors's Edgewise Therapeutics position peaked at $666K in Q4 2024.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.